Avience Biomedicals IPO Allotment Status: Check Dates, Result, Subscription, GMP & Listing Date
The Avience Biomedicals IPO allotment status is expected to be finalized on 23 June 2026. Investors who applied for the IPO can check their allotment status through the registrar, Skyline Financial Services Pvt. Ltd., once the basis of allotment is completed. The shares are scheduled to be listed on the NSE SME platform on 25 June 2026.
Avience Biomedicals IPO at a Glance
| Particulars | Details |
|---|---|
| Company | Avience Biomedicals Limited |
| IPO Type | SME IPO |
| Exchange | NSE SME |
| IPO Open Date | 18 June 2026 |
| IPO Close Date | 22 June 2026 |
| Price Band | ₹196 to ₹208 per share |
| Issue Size | ₹30.24 Crore |
| Allotment Date | 23 June 2026 |
| Refund Initiation | 24 June 2026 |
| Shares Credited to Demat | 24 June 2026 |
| Listing Date | 25 June 2026 |
| Registrar | Skyline Financial Services Pvt. Ltd. |
How to Check Avience Biomedicals IPO Allotment Status
Via Skyline Financial Services
- Visit the registrar’s IPO allotment page.
- Select Avience Biomedicals IPO from the dropdown menu.
- Choose one of the search options:
- PAN Number
- Application Number
- DP/Client ID
- Enter the required details.
- Click Search to view your allotment status.
Via NSE Website
- Visit the NSE IPO allotment portal.
- Select the issue name.
- Enter PAN details.
- Complete the verification process.
- Submit to check allotment status.
Avience Biomedicals IPO Subscription Status
The IPO witnessed an exceptionally strong response from investors, with overall subscription exceeding 385 times. Category-wise demand was as follows:
| Category | Subscription |
|---|---|
| QIB | 196.77x |
| NII/HNI | 597.62x |
| Retail Investors | 401.21x |
| Overall | 385.33x |
Such strong subscription levels generally indicate significant investor interest and may reduce allotment chances for retail applicants due to oversubscription.
Avience Biomedicals IPO GMP Today
As of the latest available grey market updates, the Grey Market Premium (GMP) is reported in the range of ₹70 to ₹72 per share. Based on the upper price band of ₹208, the estimated listing price is around ₹278 to ₹280, implying a potential premium of approximately 33% to 35% over the issue price.
GMP Snapshot
| Metric | Value |
|---|---|
| IPO Price | ₹208 |
| Latest GMP | ₹70–₹72 |
| Estimated Listing Price | ₹278–₹280 |
| Estimated Premium | 33%–35% |
Note: GMP is unofficial and can change rapidly before listing. It should not be considered a guarantee of listing gains.
Avience Biomedicals IPO Listing Date
The shares of Avience Biomedicals are scheduled to debut on the NSE SME platform on 25 June 2026. Investors who receive allotment can expect shares to be credited to their demat accounts on 24 June 2026, one day before listing.
About Avience Biomedicals
Avience Biomedicals is a healthcare and diagnostics company focused on manufacturing and supplying In-Vitro Diagnostic (IVD) products, molecular diagnostic kits, medical devices, and related healthcare solutions. The company serves pathology laboratories, hospitals, research centers, and healthcare institutions across India and overseas markets.
Key Takeaways
- IPO Opened: 18 June 2026
- IPO Closed: 22 June 2026
- Allotment Date: 23 June 2026
- Listing Date: 25 June 2026
- Overall Subscription: 385.33x
- Latest GMP: ₹70–₹72
- Estimated Listing Price: ₹278–₹280
- Registrar: Skyline Financial Services Pvt. Ltd.
FAQs
Q. When will Avience Biomedicals IPO allotment be finalized?
The basis of allotment is expected to be finalized on 23 June 2026.
Q. How can I check Avience Biomedicals IPO allotment status?
You can check it through the Skyline Financial Services website using your PAN, application number, or DP/Client ID.
Q. What is the Avience Biomedicals IPO listing date?
The shares are scheduled to list on 25 June 2026 on the NSE SME platform.
Q. What is the latest GMP of Avience Biomedicals IPO?
Recent market reports indicate a GMP of around ₹70–₹72 per share.
Q. What was the IPO subscription status?
The issue was subscribed approximately 385.33 times overall, with strong participation across retail, HNI, and institutional categories.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
